Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Shares Outstanding (2016 - 2025)

Perspective Therapeutics (CATX) has disclosed Shares Outstanding for 15 consecutive years, with $74.3 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 5.19% to $74.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $74.3 million through Dec 2025, up 5.19% year-over-year, with the annual reading at $74.3 million for FY2025, 5.19% up from the prior year.
  • Shares Outstanding hit $74.3 million in Q4 2025 for Perspective Therapeutics, roughly flat from $74.3 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $142.1 million in Q3 2022 to a low of $14.2 million in Q4 2022.
  • Historically, Shares Outstanding has averaged $84.1 million across 5 years, with a median of $74.2 million in 2025.
  • Biggest five-year swings in Shares Outstanding: skyrocketed 239407.77% in 2021 and later tumbled 89.99% in 2022.
  • Year by year, Shares Outstanding stood at $142.0 million in 2021, then crashed by 89.99% to $14.2 million in 2022, then surged by 98.3% to $28.2 million in 2023, then surged by 150.78% to $70.7 million in 2024, then rose by 5.19% to $74.3 million in 2025.
  • Business Quant data shows Shares Outstanding for CATX at $74.3 million in Q4 2025, $74.3 million in Q3 2025, and $74.3 million in Q2 2025.